Pay in 4 interest-free payments of $6.41 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
Emerging evidence on depressive-symptom reduction Intriguingly, emerging data from ongoing studies suggest that semaglutide treatment could meaningfully reduce depressive symptoms, particularly in patients with obesity-related mood disorders
The compounds quinolinium scaffold mimics nicotinamides structure, allowing it to compete for the NNMT active site while avoiding interactions with other enzymes
A 2023 review in the Journal of Clinical Endocrinology & Metabolism highlighted that GLP-1s can delay gastric emptying significantly, especially at higher doses or early in treatment.44 Another study found that just over 5% of patients experience gastroparesis and it was more likely when using liraglutide or dulaglutide when compared with semaglutide.45 A 2024 cross-sectional analysis in Pharmaceuticals examined the GI side effects of semaglutide, dulaglutide, liraglutide, and exenatide in over 10,000 adults with T2DM or obesity from the National Institutes of Health All of Us cohort.45 They found that abdominal pain was the most frequently reported GI issue (57.6%), followed by constipation, diarrhea, nausea/vomiting, GI bleeding, gastroparesis, and pancreatitis
That finding proved lowering LDL prevents heart attacks, and it handed drugmakers a target: copy that gene
Learn more in our comprehensive guide to GLP-1 medications and eye health
Peptides are small but mighty, and they are critical for total body health
